HIV
HIV-1 is an RNA retrovirus that infects immune cells through the envelope glycoprotein Env, whose mature gp120/gp41 trimer mediates viral entry into host cells[1]. Mechanistically, gp120 binds CD4 and then the chemokine coreceptors CCR5 or CXCR4, while gp41 refolding brings viral and cellular membranes together for fusion[2][3]. After entry, viral replication depends on reverse transcriptase, protease, and integrase, making these enzymes core targets for antiretroviral research[4][5]. In disease relevance, untreated HIV replication causes progressive CD4+ T-cell loss and immunological abnormalities, increasing infectious and oncological complications[6]. Compared with related forms, HIV-1 remains the main focus because it is described as the most virulent and pathogenic subtype in diagnostic and treatment literature[7]. For experimental applications, entry inhibitors target gp120, gp41, CCR5, or CXCR4, while enzyme inhibitors target reverse transcriptase, protease, or integrase to suppress distinct stages of the HIV life cycle[4][8].
References:
- [1]. Anang S, et al. Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles. J Virol. 2025 Dec 23;99(12):e0158525. [Content Brief]
- [2]. Teixeira C, et al. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem. 2011 Apr;46(4):979-92. [Content Brief]
- [3]. Princen K, et al. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. [Content Brief]
- [4]. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241. PMID: 15934866. et al. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. [Content Brief]
- [5]. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. doi: 10.1586/14787210.5.1.67. PMID: 17266455. et al. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. [Content Brief]
- [6]. Deeks SG, et al. HIV infection. Nat Rev Dis Primers. 2015 Oct 1;1:15035. [Content Brief]
- [7]. Zulfiqar HF, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017 Mar 7;5:32. [Content Brief]
- [8]. Greenberg M, et al. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol. 2004 Sep-Oct;14(5):321-37. [Content Brief]
All Product Categories
-
HIV Related Products (903)
Related Products (903)
-
Trecovirsen sodium scrambled negative control
0 ImagesCat. No.: HY-149906DTrecovirsen sodium scrambled negative control is the sequence scrambled negative control of Trecovirsen sodium.
-
R82913
0 ImagesCat. No.: HY-106872CAS No.: 126347-69-1Synonyms: 9-Cl-TIBOR82913 (9-Cl-TIBO) is a potent and high selective inhibitor of HIV-1 reverse transcriptase with antiviral activity on both an RNA template (negative strand synthesis) and a DNA template (positive strand synthesis). R82913 inhibits the replication of different strains of HIV-I in CEM cells with a median IC50 value of of 0.15 μM.
-
Tizoxanide (Standard)
0 ImagesCat. No.: HY-12687RCAS No.: 173903-47-4Synonyms: TIZ (Standard)Tizoxanide (Standard) is the analytical standard of Tizoxanide. This product is intended for research and analytical applications. Tizoxanide (TIZ) is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. Tizoxanide (TIZ) has anti-HIV-1 activities and potent inhibition of both HBV and HCV replication with values EC50 of 0.46μM and 0.15 μM, respectively. Tizoxanide also exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and suppressing of the activation of the NF-κB and the MAPK signaling pathways in LPS-treated macrophage cells.
-
Siamycin III
0 ImagesCat. No.: HY-P5568CAS No.: 152835-17-1Synonyms: RP 71955RP 71955 is an antimicrobial peptide against HIV-1.
-
Sifuvirtide
0 ImagesCat. No.: HY-P10517CAS No.: 857094-21-4Synonyms: SFT
-
Zidovudine diphosphate
0 ImagesCat. No.: HY-167716CAS No.: 106060-89-3Zidovudine diphosphate is an antiretroviral agent that exhibits the activity of inhibiting the reverse transcriptase enzyme used by HIV to synthesize DNA, thereby preventing the formation of viral DNA.
-
T-peptide
0 ImagesCat. No.: HY-P2251CAS No.: 2022956-62-1T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.
-
Epicoccone B
0 ImagesCat. No.: HY-N10294CAS No.: 1067224-41-2Epicoccone B, firstly reported from C. globosum, exhibits the DPPH free radical scavenging ability with IC50 value of 10.8 μM, and has potent α-glucosidase inhibition with IC50 value of 27.3 μM. Anti-HIV activity.
-
HIV-IN-1
0 ImagesCat. No.: HY-143478CAS No.: 2756837-91-7
-
Raltegravir-d6
0 ImagesCat. No.: HY-10353S1CAS No.: 1100750-98-8Synonyms: MK-0518-d6Raltegravir-d6 is a deuterated labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
-
5-Fluorouracil-13C4,15N2
0 ImagesCat. No.: HY-90006S3CAS No.: 202407-03-2Synonyms: 5-FU-13C4,15N25-Fluorouracil-13C4,15N2 is the 13C and 15N labeled 5-Fluorouracil. 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer. 5-Fluorouracil also inhibits HIV.
-
KFA-027
0 ImagesCat. No.: HY-178741KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections.
-
Sp-TTPαS
0 ImagesCat. No.: HY-137613CAS No.: 83199-32-0Sp-TTPαS is a competitivesterile alpha motif and HD domain containing protein 1 (SAMHD1) hydrolysis inhibitor. Sp-TTPαS competitively inhibits SAMHD1 triphosphohydrolase activity with a Ki value of 46 µM.
-
Megestrol acetate-d3-1
0 ImagesCat. No.: HY-13676S1Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway.
-
CNI-H0294 hydrochloride
0 ImagesCat. No.: HY-178833CAS No.: 180740-99-2CNI-H0294 hydrochloride is a selective HIV-1 integrase inhibitor. CNI-H0294 hydrochloride is promising for research of HIV-associated central nervous system diseases.
-
HIV-IN-3
0 ImagesCat. No.: HY-146973CAS No.: 3032454-77-3HIV-IN-3 (Compound 22a) is a potent inhibitor of HIV with an IC50 of 1.5 μM. HIV-IN-3 has the potential for the research of HIV-related diseases.
